Mycophenolic acid attenuates tumor necrosis factor-α-induced endothelin-1 production in human aortic endothelial cells

Atherosclerosis

Volumn 211, Issue 1, 2010, Pages 48-54

  Yang, Won Seok ^a   Lee, Joo Mi ^b   Han, Nam Jeong ^b   Kim, Yoon Ji ^a   Chang, Jai Won ^a   Park, Su Kil ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Institute for Life Sciences   (South Korea)

Author keywords

Aortic endothelial cell; Endothelin 1; Mycophenolic acid; P65 phosphorylation

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ACETYLCYSTEINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ENDOTHELIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 11; MYCOPHENOLIC ACID; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; ANTHRA(1,9-CD)PYRAZOL-6(2H)-ONE; ANTHRACENE DERIVATIVE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDINE DERIVATIVE; TRANSCRIPTION FACTOR AP 1;

AORTIC ENDOTHELIAL CELL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ACETYLCYSTEINE; ANTHRACENES; CELLS, CULTURED; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MYCOPHENOLIC ACID; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954312189     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.018     Document Type: Article

References (30)

1. Ojo A.O., Hanson J.A., Wolfe R.A., Leichtman A.B., Agodoa L.Y., Port F.K. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000, 57:307-313.
2. Rahmani M., Cruz R.P., Granville D.J., McManus B.M. Allograft vasculopathy versus atherosclerosis. Circ Res 2006, 99:801-815.
3. Gibson W.T., Hayden M.R. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 2007, 1110:209-221.
4. Tabas I., Williams K.J., Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007, 116:1832-1844.
5. Ivey M.E., Osman N., Little P.J. Endothelin-1 signalling in vascular smooth muscle: pathways controlling cellular functions associated with atherosclerosis. Atherosclerosis 2008, 199:237-247.
6. Achmad T.H., Rao G.S. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 1992, 189:994-1000.
7. Komuro I., Kurihara H., Sugiyama T., Yoshizumi M., Takaku F., Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988, 238:249-252.
8. Rodriguez-Vita J., Ruiz-Ortega M., Rupérez M., et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-β, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005, 97:125-134.
9. Ballinger M.L., Ivey M.E., Osman N., Thomas W.G., Little P.J. Endothelin-1 activates ETA receptors on human vascular smooth muscle cells to yield proteoglycans with increased binding to LDL. Atherosclerosis 2009, 205:451-457.
10. Winkles J.A., Alberts G.F., Brogi E., Libby P. Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993, 191:1081-1088.
11. Babaei S., Picard P., Ravandi A., et al. Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 2000, 48:158-167.
12. Little P.J., Ivey M.E., Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Curr Vasc Pharmacol 2008, 6:195-203.
13. Bullingham R.E., Nicholls A.J., Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998, 34:429-455.
14. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47:85-118.
15. Haug C., Schmid-Kotsas A., Linder T., Bachem M.G., Gruenert A., Rozdzinski E. Influence of hepatocyte growth factor, epidermal growth factor, and mycophenolic acid on endothelin-1 synthesis in human endothelial cells. Nephrol Dial Transplant 2001, 16:2310-2316.
16. Trapp A., Weis M. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 2005, 45:81-87.
17. Marsden P.A., Brenner B.M. Transcriptional regulation of the endothelin-1 gene by TNF-α. Am J Physiol 1992, 262(4 Pt 1):C854-C861.
18. Garg A.K., Aggarwal B.B. Reactive oxygen intermediates in TNF signaling. Mol Immunol 2002, 39:509-517.
19. Park J., Chang H.K., Ha H., Kim M.S., Ahn H.J., Kim Y.S. Mycophenolic acid inhibits cell proliferation and extracellular matrix synthesis in rat vascular smooth muscle cells through direct and indirect inhibition of cellular reactive oxygen species. J Surg Res 2008, 150:17-23.
20. Krötz F., Keller M., Derflinger S., et al. Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 2007, 49:201-208.
21. Viedt C., Dechend R., Fei J., Hansch G.M., Kreuzer J., Orth S.R. MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-κB and activating protein-1. J Am Soc Nephrol 2002, 13:1534-1547.
22. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998, 1:661-671.
23. DiDonato J.A., Hayakawa M., Rothwarf D.M., Zandi E., Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997, 388:548-554.
24. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65.
25. Naumann M., Scheidereit C. Activation of NF-κB in vivo is regulated by multiple phosphorylations. EMBO J 1994, 13:4597-4607.
26. Viatour P., Merville M.P., Bours V., Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 2005, 30:43-52.
27. Chen L.F., Williams S.A., Mu Y., et al. NF-κB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol 2005, 25:7966-7975.
28. Chen L.F., Mu Y., Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-κB. EMBO J 2002, 21:6539-6548.
29. Tirumurugaan K.G., Jude J.A., Kang B.N., Panettieri R.A., Walseth T.F., Kannan M.S. TNF-α induced CD38 expression in human airway smooth muscle cells: role of MAP kinases and transcription factors NF-κB and AP-1. Am J Physiol Lung Cell Mol Physiol 2007, 292:L1385-L1395.
30. Voisard R., Geçgüner L., Baur R., Herter T., Hombach V. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio. Int J Cardiol 2005, 102:435-442.